Antitumor activity of folate-targeted, paclitaxel-loaded polymeric micelles on a human esophageal EC9706 cancer cell line

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 3487-3502

  Wu, Wenbin ^a   Zheng, Yonghui ^b   Wang, Rui ^b   Huang, Weili ^c   Liu, Lei ^b   Hu, Xiuli ^b   Liu, Shi ^b   Yue, Jun ^b   Tong, Ti ^a   Jing, Xiabin ^b  

^a THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^b CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY   (China)

^c BEIHUA UNIVERSITY   (China)

Author keywords

Esophageal cancer; Folate; Paclitaxel; Polymer drug conjugate; Targeted drug delivery

Indexed keywords

CASPASE 3; DRUG CARRIER; FOLIC ACID; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CELL ASSAY; CELL TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG TARGETING; DRUG UPTAKE; ESOPHAGUS CANCER; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NICK END LABELING; NONHUMAN; POLYMERIC MICELLE; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; DRUG CARRIERS; ESOPHAGEAL NEOPLASMS; FLOW CYTOMETRY; FOLIC ACID; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; KAPLAN-MEIER ESTIMATE; MALE; MICE; MICE, NUDE; MICELLES; NANOCONJUGATES; PACLITAXEL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 84870347195     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S32620     Document Type: Article

References (46)

1. Shahbaz Sarwar CM, Luketich JD, Landreneau RJ, Abbas G. Esophageal cancer: an update. Int J Surg. 2010;8(6):417-422.
2. Jemal A, Siegel R, Ward E, etal. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
3. Anderson LL, Lad TE. Autopsy findings in squamous-cell carcinoma of the esophagus. Cancer. 1982;50(8):1587-1590.
4. Chan KW, Chan EY, Chan CW. Carcinoma of the esophagus. An autopsy study of 231 cases. Pathology. 1986;18(4):400-405.
5. Cooper JS, Guo MD, Herskovic A, etal. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999;281(17):1623-1627.
6. Minsky BD, Pajak TF, Ginsberg RJ, etal. INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20(5):1167-1174.
7. Ku GY, Ilson DH. Esophagogastric cancer: targeted agents. Cancer Treat Rev. 2010;36(3):235-248.
8. Malthaner R, Wong RK, Spithoff K. Preoperative or postoperative therapy for resectable oesophageal cancer: an updated practice guideline. Clin Oncol (R Coll Radiol). 2010;22(4):250-256.
9. Henry LR, Goldberg M, Scott W, etal. Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a Phase II report. Ann Surg Oncol. 2006;13(2):214-220.
10. Jatoi A, Martenson J, Mahoney MR, etal. Results of a planned interim toxicity analysis with trimodality therapy, including carboplatin AUC = 4, paclitaxel, 5-fluorouracil, amifostine, and radiation for locally advanced esophageal cancer: preliminary analyses and treatment recommendations from the North Central Cancer Treatment Group. Int Semin Surg Oncol. 2004;1(1):9.
11. Meluch AA, Greco FA, Gray JR, etal. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network Phase II trial. Cancer J. 2003;9(4):251-260.
12. Seung SK, Smith JW, Molendyk J, etal. Selective dose escalation of chemoradiotherapy for esophageal cancer: role of treatment intensification. Semin Oncol. 2004;31(6 Suppl 18):13-19.
13. Urba SG, Orringer MB, Ianettonni M, etal. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer. 2003;98(10):2177-2183.
14. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011;63(3):131-135.
15. Hamaguchi T, Matsumura Y, Suzuki M, etal. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer. 2005;92(7):1240-1246.
16. Lee KS, Chung HC, Im SA, etal. Multicenter Phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat. 2008;108(2):241-250.
17. Chipman SD, Oldham FB, Pezzoni G, Singer JW. Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate. Int J Nanomedicine. 2006;1:375-383.
18. Yang D, Van S, Jiang X, Yu L. Novel free paclitaxel-loaded poly(L-gamma-glutamylglutamine)-paclitaxel nanoparticles. Int J Nanomedicine. 2011;6:85-91.
19. Wang F, Chen Y, Zhang D, etal. Folate-mediated targeted and intracellular delivery of paclitaxel using a novel deoxycholic acid-O-carboxymethylated chitosan-folic acid micelles. Int J Nanomedicine. 2012;7:325-337.
20. Werner ME, Karve S, Sukumar R, etal. Folate-targeted nanoparticle delivery of chemo-and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis. Biomaterials. 2011;32(33):8548-8554.
21. Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta. 1995;1233(2):134-144.
22. Kamen BA, Smith AK. A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro. Adv Drug Deliv Rev. 2004;56(8):1085-1097.
23. Chen SZ, Liu XZ, Guo GH, etal. Research on expression of folate receptor alpha and its correlation with clinicopathology in esophageal carcinoma. Journal of Practical Oncology. 2008;23(3):200-205.
24. Huang L, Hu J, Lang L, etal. Synthesis and characterization of electroactive and biodegradable ABA block copolymer of polylactide and aniline pentamer. Biomaterials. 2007;28(10):1741-1751.
25. Tian HY, Deng C, Lin H, etal. Biodegradable cationic PEG-PEI-PBLG hyperbranched block copolymer: synthesis and micelle characterization. Biomaterials. 2005;26(20):4209-4217.
26. Deng C, Tian H, Zhang P, etal. Synthesis and characterization of RGD peptide grafted poly(ethylene glycol)-b-poly(L-lactide)-b-poly(L-glutamic acid) triblock copolymer. Biomacromolecules. 2006;7(2):590-596.
27. Lu T, Sun J, Chen X, etal. Folate-conjugated micelles and their folate-receptor-mediated endocytosis. Macromol Biosci. 2009;9(11):1059-1068.
28. Zhang X, Li Y, Chen X, etal. Synthesis and characterization of the paclitaxel/MPEG-PLA block copolymer conjugate. Biomaterials. 2005;26(14):2121-2128.
29. Xie Z, Hu X, Chen X, etal. Synthesis and characterization of novel biodegradable poly(carbonate ester)s with photolabile protecting groups. Biomacromolecules. 2008;9(1):376-380.
30. Li Q, Zhu J, Sun F, etal. Oncostatin M promotes proliferation of ovarian cancer cells through signal transducer and activator of transcription 3. Int J Mol Med. 2011;28(1):101-108.
31. Ma P, Liu S, Huang Y, etal. Lactose mediated liver-targeting effect observed by ex vivo imaging technology. Biomaterials. 2010;31(9):2646-2654.
32. Zheng Y, Wan Y, Song X, etal. Composite micelles consisting of paclitaxel-and folic acid-carrying copolymers for treatment of Lewis lung cancer. J Control Release. 2011;152 Suppl 1:e123-e124.
33. Hattori Y, Maitani Y. Enhanced in vitro DNA transfection efficiency by novel folate-linked nanoparticles in human prostate cancer and oral cancer. J Control Release. 2004;97(1):173-183.
34. Zhao D, Zhao X, Zu Y, etal. Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles. Int J Nanomedicine. 2010;5:669-677.
35. Wehbrink D, Hassig M, Ritter N, etal. Immunohistochemical demonstration of cyclooxygenase-2 (COX-2) and prostaglandin receptors EP2 and FP expression in the bovine intercaruncular uterine wall around term. Anim Reprod Sci. 2008;106(3-4):241-254.
36. Yin C, Knudson CM, Korsmeyer SJ, Van Dyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature. 1997;385(6617):637-640.
37. Jurgensmeier JM, Xie Z, Deveraux Q, etal. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A. 1998;95(9):4997-5002.
38. Szumilo J, Chibowski DA. Assessment of the predictive value of clinical and histopathological factors as well as the immunoexpression of p53 and bcl-2 proteins in response to preoperative chemotherapy for esophageal squamous cell carcinoma. Dis Esophagus. 2000;13(3):191-197.
39. Kang SY, Han JH, Lee KJ, etal. Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy. Clin Cancer Res. 2007;13(14):4146-4153.
40. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002;108(2):153-164.
41. Ismail N, Pihie AH, Nallapan M. Xanthorrhizol induces apoptosis via the up-regulation of Bax and p53in HeLa cells. Anticancer Res. 2005;25(3B):2221-2227.
42. Hsia JY, Chen CY, Chen JT, etal. Prognostic significance of caspase-3 expression in primary resected esophageal squamous cell carcinoma. Eur J Surg Oncol. 2003;29(1):44-48.
43. Jiang H, Gong M, Cui Y, etal. Upregulation of caspase-3 expression in esophageal cancer correlates with favorable prognosis: an immunohistochemical study from a high incidence area in northern China. Dis Esophagus. 2010;23(6):487-492.
44. Salvesen GS. Caspases: opening the boxes and interpreting the arrows. Cell Death Differ. 2002;9(1):3-5.
45. Ghavami S, Hashemi M, Ande SR, etal. Apoptosis and cancer: mutations within caspase genes. J Med Genet. 2009;46(8):497-510.
46. Jersmann HP, Ross KA, Vivers S, etal. Phagocytosis of apoptotic cells by human macrophages: analysis by multiparameter flow cytometry. Cytometry A. 2003;51(1):7-15.